Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | GALR2 | O43603 | 3/20 | 0.49 |
| ▸ | GALR1 | P47211 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454492 | 0.91 | TRPV1 (0.51) | TRPV1GALR2GALR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5450135 | 0.89 | SMG1 (0.52) | TRPV1TP53SMG1CHEK1CDK1 | |
| SCHEMBL5448943 | 0.88 | CHEK1 (0.54) | TRPV1SMG1CHEK1CDK2GALR2 | |
| SCHEMBL5443283 | 0.86 | TRPV1 (0.52) | TRPV1MAPTCHEK1GALR2GALR1 | |
| SCHEMBL5442078 | 0.84 | GALR2 (0.64) | TRPV1GALR2GALR1SMN1; SMN2 | |
| SCHEMBL5449394 | 0.84 | TRPV1 (0.55) | TRPV1GALR2GALR1GAA | |
| SCHEMBL5441147 | 0.80 | CTSL (0.58) | TRPV1MAPTTP53POLBCHEK1 | |
| SCHEMBL5456557 | 0.80 | LMNA (0.65) | TRPV1MAPTSMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4918407 | 0.80 | EPHX2 (0.55) | TRPV1GALR2GALR1MTOR | |
| SCHEMBL5456731 | 0.80 | PIK3CA (0.60) | TRPV1MAPTTP53POLBCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | claimed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | TRPV1 402/4885MAPT 4826/4885TP53 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.